



**First Regional Consultation on Viral Hepatitis
in the WHO European Region:
Progress on the Way to Elimination
Tbilisi, Georgia
11-13 February 2019**

**9 February 2019
Original: English**

Provisional programme

Day 1 (Monday 11 February)	
13:30 – 14:00	Registration
14:00 – 14:45	<p>Opening Session</p> <ul style="list-style-type: none"> • Welcome remarks <p style="margin-left: 20px;"><i>H.E. Mr Mamuka Bakhtadze, Prime Minister of Georgia</i></p> <p style="margin-left: 20px;"><i>H.E. Dr David Sergeenko, Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia</i></p> <p style="margin-left: 20px;"><i>Dr Nedret Emiroglu, WHO Regional Office for Europe (WHO/Europe)</i></p> <p style="margin-left: 20px;"><i>Ms Rachel Halford, World Hepatitis Alliance</i></p> <p style="margin-left: 20px;"><i>Dr Erika Duffell, European Centre for Disease Prevention and Control (ECDC)</i></p> • Review of the Meeting Objectives <p style="margin-left: 20px;"><i>Dr Masoud Dara, WHO/Europe</i></p>
14:45 – 15:00	<i>Media Coverage</i>
15:00 – 16:00	<p>Special Session: Update on Georgia HCV Elimination Program <i>Co-organized with the Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs and the National Center for Disease Control and Public Health (NCDC).</i></p> <ul style="list-style-type: none"> • Progress of the HCV Elimination Program in Georgia <p style="margin-left: 20px;"><i>Prof Amiran Gamkrelidze, NCDC (15 min)</i></p> • Hepatitis C treatment and care cascade in Georgia: monitoring progress towards elimination <p style="margin-left: 20px;"><i>Prof Tengiz Tsertsvadze, IDACIRC (15 min)</i></p> • Decentralization and integration of HCV services in primary care, hospitals and harm reduction settings in Georgia <p style="margin-left: 20px;"><i>Dr Ekaterine Adamia, Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia, (15 min)</i></p> <p>Questions and General Discussion <i>Discussion (15 min)</i></p>

16:00 – 16:30	Coffee Break	
16:30 – 18:00	Special Session: Measuring the impact of hepatitis elimination on mortality	
	<ul style="list-style-type: none"> • Chronic viral hepatitis infections and liver cancer • General approach to impact assessment using mortality and attributable fraction data • Identification and Characterization of HCV-Attributable Liver Cancer in Georgia: Methodological Approaches 	<p><i>Prof Massimo Colombo, European Association for the Study of the Liver – International Liver Foundation (EASL-ILF) (15 min)</i></p> <p><i>Dr Yvan Hutin, WHO Global Hepatitis Programme (GHP) (15 min)</i></p> <p><i>Dr Geoff Beckett, United States Centers for Disease Control and Prevention (U.S. CDC) (15 min)</i></p>
	Questions and General Discussion	
18:00 – 20:00	Reception, Marriott Courtyard Tbilisi	

Day 2 (Tuesday 12 February)

08:30 – 09:00	Registration	
09:00 – 09:40	Session 1: Introduction <ul style="list-style-type: none"> • Global updates for viral hepatitis • Regional updates and Progress Report • Hepatitis Delta (D): a neglected problem. Where are we now? 	<i>Facilitators: Dr Masoud Dara, WHO/Europe and Prof Amiran Gamkrelidze, NCDC</i> <i>Dr Yvan Hutin, WHO GHP (10 min)</i> <i>Dr Antons Mozalevskis, WHO/Europe (10 min)</i> <i>Prof Mario Rizzetto, EASL-ILF, University of Torino (20 min)</i>
09:40 – 10:30	Session 2: National Planning (1st part) <ul style="list-style-type: none"> • The role of national planning in hepatitis elimination • The impact of Iceland’s elimination program-TraP HepC (Treatment as Prevention for Hepatitis C) • Panel discussion, examples from the Region (25 minutes) 	<i>Facilitators: Dr Antons Mozalevskis, WHO/Europe and Mr Marko Korenjak, European Liver Patients’ Association</i> <i>Dr Marcelo Naveira, WHO consultant (15 min)</i> <i>Prof Sigurður Ólafsson, Iceland (10 min)</i> <i>Prof Georgios Papatheodoridis, Greece</i> <i>Dr Zuridin Nurmatov, Kyrgyzstan</i> <i>Prof Ramazan İdilman, Turkey</i>
10:30 – 11:00	Coffee Break	
11:00 – 11:45	Session 2: National Planning (2nd part) <ul style="list-style-type: none"> • Group work with hepatitis national planning check-list <u>Questions and General Discussion</u>	<i>Facilitators: Dr Yvan Hutin, WHO GHP, Dr Antons Mozalevskis, WHO/Europe and Prof Sharon Hutchinson, Glasgow Caledonian University (GCU), Scotland</i>
11:45 – 12:30	Session 3: Strategic Information <ul style="list-style-type: none"> • WHO Consolidated Strategic Information Guidelines for Viral Hepatitis • Strategic information guiding policy and practice: Scotland’s experience <u>Questions and General Discussion</u>	<i>Dr Yvan Hutin, WHO GHP (15 min)</i> <i>Prof Sharon Hutchinson, GCU (10min)</i> <i>Discussion (15 min)</i>
12:30 – 13:30	Lunch	
13:30 – 15:00	Parallel Sessions 1: Monitoring and Evaluation	

	<p>Main meeting room (Ballroom): non-EU/EEA Member States of the WHO European Region</p> <ul style="list-style-type: none"> • Global Reporting System for Hepatitis (GRSH): data extraction and data entry • Panel discussion: challenges with viral hepatitis data collection and reporting to GHRS • Work in groups with facilitators on GRSH (filling the reporting form and data entry) <p>Meeting room 2: EU/EEA Member States of the WHO European Region</p> <ul style="list-style-type: none"> • Rollout of the EU monitoring system for hepatitis B and C • The EMCDDA monitoring system for hepatitis B and C among people who inject drugs • Country feedback (20–30 min) <p><u>Moderated discussion (40–50 min)</u></p>	<p><i>Facilitators: Dr Yvan Hutin, WHO GHP and Dr Antons Mozalevskis, WHO/Europe</i></p> <p><i>Dr Yvan Hutin, WHO GHP (30 min)</i> <i>Panel discussion (30 min), countries that have experience in GRSH reporting</i></p> <ul style="list-style-type: none"> - Switzerland - Kyrgyzstan - Georgia (TBC) <p><i>Working groups (30 min)</i></p> <p><i>Facilitator: Dr Erika Duffell, ECDC, Dr Thomas Seyler, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and Dr Masoud Dara, WHO/Europe</i></p> <p><i>Dr Erika Duffell, ECDC (10 min)</i></p> <p><i>Dr Thomas Seyler, EMCDDA (10 min)</i></p> <ul style="list-style-type: none"> - Slovenia - The Netherlands - Germany (TBC) <p><i>Discussion (40 min)</i></p>
15:00 – 15:30	Coffee Break	
15:30 – 17:15	<p>Session 4: Delivering for Equity</p> <ul style="list-style-type: none"> • WHO Working Group on Hepatitis in Substance Users • Global State of Harm Reduction (focus on WHO European Region) • Elimination of viral hepatitis in prison settings • The role of civil society in viral hepatitis response among people who use drugs • Panel discussion: case studies from Region 	<p><i>Facilitators: Ms Ganna Dovbakh, Eurasian Harm Reduction Association (EHRA) and Dr Antons Mozalevskis, WHO/Europe</i></p> <p><i>Dr Antons Mozalevskis, WHO/Europe (10 min)</i></p> <p><i>Mr Sam Shirley-Beavan, Harm Reduction International (10 min)</i></p> <p><i>Dr Fadi Meroueh, Centre Hospitalier Régional Universitaire, Montpellier, France (10 min)</i></p> <p><i>Mr Eberhard Schatz, Correlation European Harm Reduction Network (10 min)</i></p> <p><i>Panel Discussion 30 min</i></p> <p><i>Dr Ruth Zimmermann, Germany</i></p>

		<p><i>Dr Lars Peters, CHIP, WHO Collaborating Centre on HIV and Viral Hepatitis, Denmark</i> <i>Ms Iryna Ivanchuk, Ukraine</i></p> <p><u>Questions and General discussion (20 min)</u> <i>Discussion (20 min)</i></p>
19:00 – 21:00	Meeting dinner at “Old Metekhi”	
Day 3 (Wednesday 13 February)		
09:00 – 10:30	<p>Session 5: Hepatitis B control through immunization</p> <ul style="list-style-type: none"> • Regional targets on hepatitis B control through immunization and prevention of perinatal transmission • Validation of the achievement of regional targets and the role of serosurveys <p>Country presentations (10 min each):</p> <p><u>Questions and General discussion (20 min)</u></p>	<p><i>Facilitators: Ms Greet Hendricks, Viral Hepatitis Prevention Board and Dr Sandra Dudareva, ETAGE working group on hepatitis B</i></p> <p><i>Dr Antons Mozalevskis, WHO/Europe (15 min)</i></p> <p><i>Dr Sandra Dudareva, ETAGE working group on hepatitis B (15 min)</i></p> <p><i>Dr Irene Veldhuijzen, the Netherlands</i> <i>Dr Raina Nikiforova, Latvia</i> <i>Dr Maria Elena Tosti, Italy</i></p> <p><i>Discussion (20 min)</i></p>
10:30 – 11:00	Coffee Break	
11:00 – 12:30	<p>Session 6: Testing/Linkage to Care and Diagnostics</p> <ul style="list-style-type: none"> • WHO Guidelines on hepatitis B and C testing • Public health guidance on HIV, hepatitis B and C testing in EU/EEA • HCV diagnostic decentralization and simplification and technology landscape • Panel discussion (30 min) <p><u>Questions and General discussion (15 min)</u></p>	<p><i>Facilitators: Dr Ana Avellon, WHO European Laboratory Initiative Core Group, Dr Yvan Hutin WHO GHP</i> <i>Dr Antons Mozalevskis, WHO/Europe (15 min)</i></p> <p><i>Dr Erika Duffell, ECDC (10 min)</i></p> <p><i>Dr Beatrice Vetter, Foundation for Innovative New Diagnostics (FIND) (20 min)</i></p> <p><i>Prof Krzysztof Tomaszewicz, Poland</i> <i>Prof Cora Pop, Romania</i> <i>Dr Isable Aldir, Portugal</i> <i>Prof Hasmik Ghazinyan, Armenia</i></p> <p><i>Discussion (15 min)</i></p>
12:30 – 13:30	Lunch	

13:30 – 15:00	<p>Session 7: Treatment/service delivery and access to treatment under Universal Health Coverage</p> <ul style="list-style-type: none"> • WHO Guidelines for HBV and HCV, focus on simplification and scale up • Access to medicines, including generic medicines, in countries of WHO European Region • Challenges and opportunities to scale-up HCV treatments • UNDP support to countries to increase access to hepatitis treatment • UNICEF support to countries to increase access to hepatitis diagnostics and treatment • Panel discussion examples from Region (30 min): 	<p><i>Facilitators: Dr Erkin Checheibaev, Kyrgyzstan and Dr Antons Mozalevskis, WHO/Europe</i></p> <p><i>Dr Marcelo Naveira, WHO consultant (15 min)</i></p> <p><i>Ms Liudmyla Maistat, Medicines Patents Pool (MPP), (10 min)</i></p> <p><i>Dr Pascale Boulet, Drugs for Neglected Diseases initiative (DNDi) (10 min)</i></p> <p><i>Dr Cecile Mace, UNDP (10 min)</i></p> <p><i>Dr Alok Sharma, UNICEF (10 min)</i></p> <p><i>Prof Igor Karpov, Belarus</i> <i>Prof Elena Esaulenko, Russian Federation Country #3 (TBC)</i></p>
15:00 – 15:30 Coffee Break		
15:30 – 16:15	<p>Group discussions: Access to Diagnosis and Treatment</p> <p>Group 1: Countries with patent protection</p> <p>Group 2: Countries without strong patent protection</p> <p>Group 3: Countries included in voluntary licence agreements</p>	<p><i>Facilitators: Hon Dr Ricardo Baptista Leite, UNITE; Dr Yvan Hutin, WHO GHP and Dr Cécile Macé, UNDP</i></p> <p><i>Facilitators: Dr Pascale Boulet, DNDi and Dr Maisoon Elbukhari, UNDP</i></p> <p><i>Facilitators: Ms Ludmila Maistat, MPP and Dr Marion Baudry, UNDP</i></p>
16:15 – 17:15	<p>Session 8: Financing / Partnerships and Integration</p> <ul style="list-style-type: none"> • WHO Hep C Calculator and Global Price Tag for hepatitis Elimination • Panel discussion: the role of partnerships for hepatitis response in the WHO European region (30 min) <p><u>Questions and General discussion (15 min)</u></p>	<p><i>Facilitators: Dr Antons Mozalevskis, WHO/Europe and Georgia representative (TBC)</i></p> <p><i>Dr Yvan Hutin, WHO GHP (15 min)</i></p> <p><i>Dr Geoff Beckett, U.S. CDC</i> <i>Hon Dr Ricardo Baptista Leite, UNITE</i> <i>Dr Michael Favorov, Global Task Force</i> <i>Dr Tatjana Reic, ACHIEVE coalition</i></p> <p><i>Discussion (15 min)</i></p>
17:15 – 17:30 Closing Session		